Patents by Inventor Mark Connors
Mark Connors has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220368283Abstract: A power management circuit supporting phase correction in an analog signal is disclosed. The power management circuit includes a power amplifier circuit configured to amplify an analog signal having a time-variant power envelope based on a modulated voltage. The power management circuit also includes an envelope tracking (ET) integrated circuit (ETIC) configured to generate the modulated voltage and a modulated phase correction voltage to thereby cause a phase change in the analog signal. In embodiments disclosed herein, a correlation between the time-variant power envelope, the modulated voltage, and the modulated phase correction voltage is explored to thereby allow the ETIC to generate the modulated voltage and the modulated phase correction voltage based on the time-variant power envelope. As a result, it is possible to enable good time and phase alignment between the modulated voltage and the time-variant power envelope to thereby improve efficiency and linearity of the power amplifier circuit.Type: ApplicationFiled: November 29, 2021Publication date: November 17, 2022Inventors: Andrew F. Folkmann, Nadim Khlat, Mark Connor
-
Publication number: 20220280019Abstract: A lint brush includes a housing and a lint tool having a lint-removing material. The lint tool is movable along a longitudinal axis of the housing between a stowed position where the lint tool is housed in the housing and a deployed position where the lint tool is extended from the housing. The lint tool is rotatable relative to the longitudinal axis from the deployed position to a first rotated position. An actuator is mounted to one of the housing and the lint tool. The actuator is configured to move the lint tool from the first rotated position back to the deployed position.Type: ApplicationFiled: March 2, 2021Publication date: September 8, 2022Inventors: Daniel John Connors, Conor Patrick McNamara, Benjamin Beck, Douglas A. Marsden, Ryan Donovan, Michael McDuffee, Jonathan Mark Liston, Phillip Seagram, Marina Eaves
-
Publication number: 20220098268Abstract: Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (V?) domain, a TCR variable beta domain (V?) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.Type: ApplicationFiled: January 15, 2020Publication date: March 31, 2022Inventors: Peter RHODE, Mark CONNORS, Stephen MIGUELES
-
Publication number: 20220098286Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: December 14, 2021Publication date: March 31, 2022Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Patent number: 11236152Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: November 3, 2016Date of Patent: February 1, 2022Assignees: The United States of America, as represented by the Sectetary, Department of Health and Human Services, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20210324053Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: June 25, 2021Publication date: October 21, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20200399369Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.Type: ApplicationFiled: April 8, 2020Publication date: December 24, 2020Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
-
Patent number: 10815295Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: July 24, 2018Date of Patent: October 27, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20200231658Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: February 10, 2020Publication date: July 23, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20200054765Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.Type: ApplicationFiled: October 21, 2019Publication date: February 20, 2020Inventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
-
Patent number: 10562960Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: March 18, 2016Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20190077849Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: November 3, 2016Publication date: March 14, 2019Applicants: The Trustees of Columbia University in the City of New York, The United States of AMerica, as represented by the Secretary, Department of Health and Human SercInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20190054182Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, where in a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.Type: ApplicationFiled: October 24, 2016Publication date: February 21, 2019Applicants: Sanofi, The USA, as Represented by the Secretary, Department of Health and Human ServicesInventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
-
Publication number: 20190016786Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: July 24, 2018Publication date: January 17, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20180298083Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: March 18, 2016Publication date: October 18, 2018Applicant: The United States of America, as repsented By the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 10047148Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: September 8, 2017Date of Patent: August 14, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 10047147Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 4, 2014Date of Patent: August 14, 2018Assignee: The United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose
-
Patent number: 10035845Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: GrantFiled: July 27, 2017Date of Patent: July 31, 2018Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of WashingtonInventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
-
Patent number: 10035844Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: June 2, 2017Date of Patent: July 31, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Patent number: 9896620Abstract: The present invention provides for coating proppants, such as sand, with a resin-containing dispersion which dramatically reduces the dust generated during handling, for example in hydraulic fracturing, by protecting the surface of the particle from abrasion and degradation. Such resin-containing dispersion coated-sand may also reduce the wear on metal parts used in transporting such proppants.Type: GrantFiled: February 18, 2016Date of Patent: February 20, 2018Assignee: Covestro LLCInventors: David P. Zielinski, Emery Yuhas, Yanan Chen, Derick Henderson, Mark Connor